Article Text

Download PDFPDF
Combination therapy with candesartan and lisinopril was more effective than monotherapy in type 2 diabetes and hypertension

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: What are the effects of candesartan or lisinopril, or both, on blood pressure and the urinary albumin excretion rate in patients with hypertension, microalbuminuria, and type 2 diabetes mellitus?


Randomised (unclear allocation concealment*), double blind (investigators and patients),* controlled trial with 24 weeks follow up.


37 centres in tertiary hospitals and primary care sites (12 in Australia, 9 in Denmark, 4 in Finland, and 12 in Israel).


199 patients between 30 and 75 years of age with type 2 diabetes, microalbuminuria (urinary albumin to creatinine ratio between 2.5 and 25 mg/mmol), and diastolic blood pressure (BP) between 90 and 110 mm Hg while receiving placebo. Exclusion criteria included body mass index ≥40 kg/m2, systolic BP >200 mm Hg, non-diabetic cause of secondary hypertension, cardiovascular event in the previous 6 months, increased serum creatinine and potassium concentrations, and haemoglobin A1c concentrations >10%. 197 patients (99%) (mean age 60 y, 65% …

View Full Text


  • Source of funding: AstraZeneca, Mölndal, Sweden.

  • For correspondence: Dr C E Mogensen, Kommunehospitalet, University Hospital, DK-8000 Aarhus C, Denmark. Fax +45 8949 2010.

  • * See glossary.